For people considering ibogaine-assisted therapy for 7-OH, kratom, or opioid dependence. What it is. How it works. What it costs. Where to go. And the things most clinics don't tell you upfront.
A psychoactive alkaloid from the Tabernanthe iboga root that acts on multiple receptor systems simultaneously — which is why it can address opioid dependence where single-mechanism drugs fail.
Used in Central African traditional medicine for generations. Entered Western addiction research in the 1960s. Currently Schedule I in the United States, unscheduled or legally accessible in Mexico, Canada, Costa Rica, Portugal, New Zealand, South Africa, and several other countries where licensed clinics operate.
Ibogaine is not recreational. The experience typically lasts 12–24 hours, involves autobiographical "life review," and is physically demanding. Medical supervision is non-negotiable due to cardiac risks (QT interval prolongation).
The active metabolite, noribogaine, has a 28–49 hour half-life and sustains therapeutic effects for days after the primary experience ends.
The mu-opioid mechanism transfer is pharmacologically sound — ibogaine addresses the opioid component of dependence effectively, and this should translate to 7-OH since 7-OH binds the same receptors (at 13× the potency of morphine).
But kratom's dual alkaloid profile means withdrawal has a stimulant-like component (from mitragynine) that pure opioid withdrawal doesn't have. Ibogaine's effect on this secondary layer is not well studied.
Clinical framework exists — Collin Schwartz authored the only published framework for 7-OH dependence treatment using ibogaine-assisted therapy, based on personal experience and clinical collaboration at Ambio Life Sciences. But a published framework is not the same as peer-reviewed outcome data. Go in informed.
Practical implication: if you're considering ibogaine for 7-OH, choose a clinic that (a) has experience with kratom cases specifically, (b) offers robust integration support for the longer dual-withdrawal PAWS, and (c) doesn't overclaim efficacy.